

# Imatinib Drugs-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/I130E5D9446EN.html>

Date: February 2018

Pages: 136

Price: US\$ 3,480.00 (Single User License)

ID: I130E5D9446EN

## Abstracts

### Report Summary

Imatinib Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Imatinib Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Imatinib Drugs 2013-2017, and development forecast 2018-2023

Main market players of Imatinib Drugs in Europe, with company and product introduction, position in the Imatinib Drugs market

Market status and development trend of Imatinib Drugs by types and applications

Cost and profit status of Imatinib Drugs, and marketing status

Market growth drivers and challenges

The report segments the Europe Imatinib Drugs market as:

Europe Imatinib Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Imatinib Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Capsules

Tablets

Europe Imatinib Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Drug Stores

Other

Europe Imatinib Drugs Market: Players Segment Analysis (Company and Product introduction, Imatinib Drugs Sales Volume, Revenue, Price and Gross Margin):

Apotex Inc.

Novartis

Sanofi S.A.

Cipla Inc.

Mylan Pharms Inc.

Glenmark Pharmaceuticals Ltd.

Sun Pharmaceuticals

Actavis Generics

Dr. Reddy's Laboratories

Teva Pharmaceutical Industries Ltd.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF IMATINIB DRUGS**

- 1.1 Definition of Imatinib Drugs in This Report
- 1.2 Commercial Types of Imatinib Drugs
  - 1.2.1 Capsules
  - 1.2.2 Tablets
- 1.3 Downstream Application of Imatinib Drugs
  - 1.3.1 Hospitals
  - 1.3.2 Drug Stores
  - 1.3.3 Other
- 1.4 Development History of Imatinib Drugs
- 1.5 Market Status and Trend of Imatinib Drugs 2013-2023
  - 1.5.1 Europe Imatinib Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Imatinib Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Imatinib Drugs in Europe 2013-2017
- 2.2 Consumption Market of Imatinib Drugs in Europe by Regions
  - 2.2.1 Consumption Volume of Imatinib Drugs in Europe by Regions
  - 2.2.2 Revenue of Imatinib Drugs in Europe by Regions
- 2.3 Market Analysis of Imatinib Drugs in Europe by Regions
  - 2.3.1 Market Analysis of Imatinib Drugs in Germany 2013-2017
  - 2.3.2 Market Analysis of Imatinib Drugs in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Imatinib Drugs in France 2013-2017
  - 2.3.4 Market Analysis of Imatinib Drugs in Italy 2013-2017
  - 2.3.5 Market Analysis of Imatinib Drugs in Spain 2013-2017
  - 2.3.6 Market Analysis of Imatinib Drugs in Benelux 2013-2017
  - 2.3.7 Market Analysis of Imatinib Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Imatinib Drugs in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Imatinib Drugs in Europe 2018-2023
  - 2.4.2 Market Development Forecast of Imatinib Drugs by Regions 2018-2023

### **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole Europe Market Status by Types
  - 3.1.1 Consumption Volume of Imatinib Drugs in Europe by Types

- 3.1.2 Revenue of Imatinib Drugs in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Germany
  - 3.2.2 Market Status by Types in United Kingdom
  - 3.2.3 Market Status by Types in France
  - 3.2.4 Market Status by Types in Italy
  - 3.2.5 Market Status by Types in Spain
  - 3.2.6 Market Status by Types in Benelux
  - 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Imatinib Drugs in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Imatinib Drugs in Europe by Downstream Industry
- 4.2 Demand Volume of Imatinib Drugs by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Imatinib Drugs by Downstream Industry in Germany
  - 4.2.2 Demand Volume of Imatinib Drugs by Downstream Industry in United Kingdom
  - 4.2.3 Demand Volume of Imatinib Drugs by Downstream Industry in France
  - 4.2.4 Demand Volume of Imatinib Drugs by Downstream Industry in Italy
  - 4.2.5 Demand Volume of Imatinib Drugs by Downstream Industry in Spain
  - 4.2.6 Demand Volume of Imatinib Drugs by Downstream Industry in Benelux
  - 4.2.7 Demand Volume of Imatinib Drugs by Downstream Industry in Russia
- 4.3 Market Forecast of Imatinib Drugs in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMATINIB DRUGS**

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Imatinib Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 IMATINIB DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

- 6.1 Sales Volume of Imatinib Drugs in Europe by Major Players
- 6.2 Revenue of Imatinib Drugs in Europe by Major Players
- 6.3 Basic Information of Imatinib Drugs by Major Players
  - 6.3.1 Headquarters Location and Established Time of Imatinib Drugs Major Players
  - 6.3.2 Employees and Revenue Level of Imatinib Drugs Major Players
- 6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 IMATINIB DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Apotex Inc.

7.1.1 Company profile

7.1.2 Representative Imatinib Drugs Product

7.1.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Apotex Inc.

7.2 Novartis

7.2.1 Company profile

7.2.2 Representative Imatinib Drugs Product

7.2.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.3 Sanofi S.A.

7.3.1 Company profile

7.3.2 Representative Imatinib Drugs Product

7.3.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.

7.4 Cipla Inc.

7.4.1 Company profile

7.4.2 Representative Imatinib Drugs Product

7.4.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Cipla Inc.

7.5 Mylan Pharms Inc.

7.5.1 Company profile

7.5.2 Representative Imatinib Drugs Product

7.5.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Mylan Pharms Inc.

7.6 Glenmark Pharmaceuticals Ltd.

7.6.1 Company profile

7.6.2 Representative Imatinib Drugs Product

7.6.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Glenmark

Pharmaceuticals Ltd.

7.7 Sun Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Imatinib Drugs Product

7.7.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sun Pharmaceuticals

7.8 Actavis Generics

7.8.1 Company profile

7.8.2 Representative Imatinib Drugs Product

- 7.8.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Actavis Generics
- 7.9 Dr. Reddy's Laboratories
  - 7.9.1 Company profile
  - 7.9.2 Representative Imatinib Drugs Product
  - 7.9.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories
- 7.10 Teva Pharmaceutical Industries Ltd.
  - 7.10.1 Company profile
  - 7.10.2 Representative Imatinib Drugs Product
  - 7.10.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMATINIB DRUGS**

- 8.1 Industry Chain of Imatinib Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMATINIB DRUGS**

- 9.1 Cost Structure Analysis of Imatinib Drugs
- 9.2 Raw Materials Cost Analysis of Imatinib Drugs
- 9.3 Labor Cost Analysis of Imatinib Drugs
- 9.4 Manufacturing Expenses Analysis of Imatinib Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF IMATINIB DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

### 12.1 Methodology/Research Approach

#### 12.1.1 Research Programs/Design

#### 12.1.2 Market Size Estimation

#### 12.1.3 Market Breakdown and Data Triangulation

### 12.2 Data Source

#### 12.2.1 Secondary Sources

#### 12.2.2 Primary Sources

### 12.3 Reference

## I would like to order

Product name: Imatinib Drugs-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/l130E5D9446EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l130E5D9446EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970